Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBIT (2016 - 2021)

Historic EBIT for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $44.5 million.

  • Neurocrine Biosciences' EBIT rose 20045.15% to $44.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $94.5 million, marking a year-over-year decrease of 3249.18%. This contributed to the annual value of $72.3 million for FY2019, which is 9591.54% up from last year.
  • According to the latest figures from Q3 2021, Neurocrine Biosciences' EBIT is $44.5 million, which was up 20045.15% from $62.8 million recorded in Q2 2021.
  • Neurocrine Biosciences' EBIT's 5-year high stood at $90.1 million during Q3 2019, with a 5-year trough of -$101.0 million in Q1 2019.
  • For the 5-year period, Neurocrine Biosciences' EBIT averaged around $11.5 million, with its median value being $26.7 million (2018).
  • Per our database at Business Quant, Neurocrine Biosciences' EBIT plummeted by 28323.82% in 2017 and then skyrocketed by 195745.14% in 2019.
  • Neurocrine Biosciences' EBIT (Quarter) stood at $11.8 million in 2017, then soared by 84.81% to $21.9 million in 2018, then surged by 123.05% to $48.8 million in 2019, then crashed by 190.81% to -$44.3 million in 2020, then surged by 200.45% to $44.5 million in 2021.
  • Its EBIT stands at $44.5 million for Q3 2021, versus $62.8 million for Q2 2021 and $31.5 million for Q1 2021.